Business
Board and Management Appointments
Board and Management Appointments.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 16 September 2022\n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n Board and Management Appointments\n \n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on\n developing first in class drugs in the high value and high growth oncology segment\n , is pleased to announce that further to the completion of its acquisition of the entire issued share capital of Oncogeni Limited (\"Oncogeni\")\n as announced earlier today the following board appointments:\n \n \n \n \n \n ·\n Trevor Ajanthan (Ajan) Reginald as Executive Director and Chief Executive Officer;\n \n \n ·\n Professor Sir Martin Evans as Executive Director and Group Chief Scientific Officer; and\n \n \n ·\n Dr Darrin Disley as Non-Executive Director.\n \n \n \n \n \n In addition, Roquefort Therapeutics is pleased to announce the appointment of Professor Armand Keating FRCPC, MD as an independent Chief Medical Advisor (as a non-board position).\n \n \n \n \n \n Further, as previously announced, Mark Freeman has today resigned as a Non-Executive director of the Company.\n \n \n \n \n \n \n Commenting on the appointments, Stephen West, Executive Chairman, said:\n \n \n \n \n \"I would like to welcome Ajan Reginald, Professor Sir Martin Evans and Dr Darrin Disley to the Board of Roquefort Therapeutics, and Professor Armand Keating as our new Chief Medical Officer. We are building a world class team with a proven track record in drug development who will help drive innovation and ultimately value in our exciting portfolio of oncology drugs. Sir Martin Evans is a pioneer in stem cells and DNA research and his experience will be incredibly valuable as Group Chief Scientific Officer throughout our preclinical studies. Ajan Reginald's experience in commercialisation both within big pharma and in biotech will be invaluable as CEO as we look to achieve value in this high growth segment of life sciences. Dr Darrin Disley is a great addition as Non-Executive Director, and his expertise in fundraising and value creation is incredibly complementary to our existing Board of Directors. Professor Keating is a renowned expert in anti-cancer cell therapy, a key area of Roquefort Therapeutics' ...